<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696304</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00170-49</org_study_id>
    <secondary_id>2015-05</secondary_id>
    <nct_id>NCT02696304</nct_id>
  </id_info>
  <brief_title>The Metabolic Syndrome Among Leukemia Survivors: Physiopathological Analysis</brief_title>
  <acronym>LEAMS</acronym>
  <official_title>The Metabolic Syndrome Among Childhood Acute Leukemia Survivors: Physiopathological Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Along with the improvement of childhood acute leukemia treatment, survival rates have&#xD;
      increased. Therefore, the number of long term childhood leukemia survivors has increased&#xD;
      progressively over the last decades. So, the assessment of long term health status in this&#xD;
      population becomes very important. Many studies have shown an increased risk of life&#xD;
      threatening late complications and early mortality. Cardiovascular morbidity and mortality&#xD;
      are particularly frequent. Among these late complications, the metabolic syndrome (MS) is an&#xD;
      important concern since it is associated with cardiovascular morbidity and mortality. The&#xD;
      overall MS prevalence in the French prospective cohort of survivors of childhood acute&#xD;
      leukemia was 9.2% and 18.6% in cases of total body irradiation (TBI) during the leukemia&#xD;
      treatment. Since the median age at MS evaluation was 21 years, this prevalence was very high.&#xD;
      Anyway, the MS pathophysiology in this population is still poorly understood. One of the most&#xD;
      recent hypothesis about the MS mechanism is based on the adipose tissue inability to store&#xD;
      fatty acids: when adipose tissue cannot expanse further to store excess nutriments then&#xD;
      lipids accumulate in other tissues. This ectopic lipids accumulation can cause insulin&#xD;
      resistance and MS.&#xD;
&#xD;
      The investigators hypothesized that the adipose tissue could be damaged by treatments&#xD;
      received during childhood acute leukemia treatment (particularly TBI). This leads to&#xD;
      morphological and functional abnormalities that could promote the insulin resistance and MS.&#xD;
&#xD;
      This ectopic adipose tissue contains less preadipocytes, which could impair its functional&#xD;
      properties.&#xD;
&#xD;
      The primary endpoint of this study is to compare the morphological and functional&#xD;
      characteristics of adipose tissue in patients with a MS who received or not TBI during&#xD;
      childhood leukemia treatment . This comparison will focus on:&#xD;
&#xD;
        -  The adipose tissue repartition and evaluation of the ectopic adipose tissue&#xD;
&#xD;
        -  Fibrosis and inflammation of the adipose tissue&#xD;
&#xD;
        -  Preadipocytes quantification&#xD;
&#xD;
      The secondary endpoint is to describe:&#xD;
&#xD;
        -  for the whole cohort of included patients,&#xD;
&#xD;
        -  the clinical and biological characteristics associated with the MS.&#xD;
&#xD;
        -  Cardiovascular risk factors and nutritional statement&#xD;
&#xD;
        -  Anthropometric measurements&#xD;
&#xD;
        -  Detection of other endocrinal abnormalities possibly associated with the MS&#xD;
&#xD;
        -  Analysis of inflammation blood markers and adipokines quantification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enroled patients (both groups) will be evaluated for the following criteria. Then, a&#xD;
      comparison between both groups will be performed.&#xD;
&#xD;
      1. Primary endpoint: the following factors will be studied, and compared between both groups&#xD;
      (with or without TBI):&#xD;
&#xD;
        -  Adipose tissue repartition using biphotonic absorptiometry and abdominal MRI&#xD;
&#xD;
        -  Ectopic adipose tissue evaluation (visceral and hepatical) using MRI and proton&#xD;
           spectroscopy&#xD;
&#xD;
        -  Adipose tissue inflammation (using PCR array) : quantification of the following&#xD;
           biomarkers: alpha TNF, IL6, IL1beta, IL10, MCP1, leptine and adiponectine&#xD;
&#xD;
        -  Adipose tissue fibrosis (PCR array): quantification of the following markers of&#xD;
           fibrosis: Col 1a1, Col 3a1, Col 6a1, Col 6a3, Tenascin C, Lumican, TGF beta&#xD;
&#xD;
        -  Preadipocytes quantification in the adipose tissue (immunohistochemistery)&#xD;
&#xD;
      Concerning the secondary endpoints, the following points will be studied :&#xD;
&#xD;
        -  Cardiovascular risk factors and nutritional statement&#xD;
&#xD;
        -  Anthropometric measurements&#xD;
&#xD;
        -  Other endocrinal abnormalities possibly associated with the MS&#xD;
&#xD;
        -  Analysis of inflammation blood markers and adipokines quantification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of fat mass (Biphotonic absorptiometry)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the amount of intra liver and pancreatic triglycerides (%) (proton spectroscopy, expressed as percent related to liver or pancreatic water content)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrosis and inflammation analyses of the adipose tissu : fibrosis and inflammation gene expression analyses by RQ-PCR</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Preadipocytes quantification in the adipose tissue by immunohistochemistery, expressed as percent of stroma vascular fraction of the adipose tissue</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>TBI for childhood leukemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a metabolic syndrom who received TBI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No TBI for childhood leukemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a metabolic syndrom without previousTBI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adipose tissu repartition</intervention_name>
    <description>absorptiometry,</description>
    <arm_group_label>No TBI for childhood leukemia</arm_group_label>
    <arm_group_label>TBI for childhood leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visceral and liver adipose tissue repartition</intervention_name>
    <description>MRI,spectroscopy,</description>
    <arm_group_label>No TBI for childhood leukemia</arm_group_label>
    <arm_group_label>TBI for childhood leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preadipocyte quantification and adipose tissue inflamation</intervention_name>
    <description>biopsy</description>
    <arm_group_label>No TBI for childhood leukemia</arm_group_label>
    <arm_group_label>TBI for childhood leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inflamation blood markers quantification</intervention_name>
    <description>blood drawn,</description>
    <arm_group_label>No TBI for childhood leukemia</arm_group_label>
    <arm_group_label>TBI for childhood leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age superior or equal to 18 years&#xD;
&#xD;
          -  Metabolic syndrome: at least 3 criteria among the following:&#xD;
&#xD;
               1. Waist circumference ≥ 102 cm for male and ≥ 88 cm for female)&#xD;
&#xD;
               2. High triglyceride level ≥ 150 mg/dl (1,7 mmol/l) or undergoing treatment for that&#xD;
                  affection&#xD;
&#xD;
               3. Low HDL-Cholesterol &lt; 40 mg/dl (1,03 mmol/l) for male ; &lt; 50 mg/dl (1,3 mmol/l)&#xD;
                  for femal, or undergoing treatment for that affection&#xD;
&#xD;
               4. Elevated blood pressure: systolic ≥ 130 mmHg and/or diastoloic ≥ 85 mmHg or&#xD;
                  undergoing treatment for that affection&#xD;
&#xD;
               5. Elevated fasten glucose≥ 100 mg/dl or undergoing treatment for that affection&#xD;
&#xD;
          -  Acute leukemia during childhood (under 18 years of age at the time of leukemia&#xD;
             diagnosis)&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  incomplete evaluation of metabolic syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle DESALBRES</last_name>
    <role>Study Director</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire OUDIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire OUDIN, MD</last_name>
    <email>claire.oudin@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Oudin</last_name>
      <email>claire.oudin@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Oudin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

